Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice

Marascio, Nadia; Rotundo, Salvatore; Quirino, Angela; Matera, Giovanni; Liberto, Maria Carla; Costa, Chiara; Russo, Alessandro; Trecarichi, Enrico Maria; Torti, Carlo

doi:10.3748/wjg.v28.i12.1226

Cited by 4 publications

(2 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Modified Child-Pugh's classification. 1 Scoring system: 5-6 points, grade A; 7-9 points, grade B; 10-15 points, grade C. 2 HE: hepatic encephalopathy; Grade 0: sub-clinical hepatic encephalopathy, SHE, unraveled by Retain tests A or B; Grade 1: anxiety, irritability, depression, impaired concentration, sleep disturbances; Grade 2: disorientation, poor short-term memory, disinhibited behavior, drowsiness; Grade 3: somnolence, bizarre behavior, confusion, amnesia, paranoia; Grade 4: Coma. 3 PT, Prothrombin Time, also expressed in seconds prolonged < 4; 4-6; > 6.…”

Section: Blood Sampling and Analysismentioning

confidence: 99%

“…It comprises autoimmune hepatitis, both of which induce ongoing liver damage. There are over 350 million chronic HBV carriers, nearly 71 million people infected with HCV and 20 million people infected with HEV worldwide 1 . Persistent damage to the liver may trigger liver cirrhosis (LC), i.e., a stage of partial loss of liver structure and function and potentially life-threatening complications 2 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum ApoB/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma

Cai,

Peng,

Xiao

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Clinical research has suggested that chronic HBV infection exerts a certain effect on the occurrence of cardiovascular disease by regulating cholesterol metabolism in liver cells. High serum apolipoprotein B/apolipoprotein A1 (ApoB/ApoA1) ratio plays a certain role in the above regulation, and it serves as a risk factor for cardiovascular disease. However, whether the ApoB/ApoA1 ratio is correlated with chronic HBV infection and its disease progression remains unclear. In accordance with the inclusion and exclusion criteria, all 378 participants administrated at Renmin Hospital of Wuhan University from March 2021 to March 2022, fell into Healthy Control (HC) group (50 participants), Hepatocellular carcinoma (HCC) group (107 patients), liver cirrhosis (LC) group (64 patients), chronic hepatitis B (CHB) group (62 patients), chronic hepatitis C (CHC) group (46 patients) and Hepatitis E Virus (HEV) group (49 patients). Serum ApoA1 and ApoB concentrations were measured at admission, and the ApoB/ApoA1 ratio was determined. The levels of laboratory parameters in the respective group were compared and ApoB/ApoA1 ratios in HCC patients and LC patients with different severity were further analyzed. ROC curves were plotted to analyze the early diagnostic ability of ApoB/ApoA1 ratio for HBV-associated HCC. Logistic regression and restricted cubic spline analysis were used to explore the correlation between ApoB/ApoA1 ratio and LC and HCC risk. A comparison was drawn in terms of ApoB/ApoA1 ratio between the groups, and the result was expressed in descending sequence: HEV group > CHB group > LC group > HCC group > CHC group > HC group, early-stage HCC < middle-stage HCC < advanced-stage HCC, Class A LC < Class B LC < Class C LC. Serum ApoB/ApoA1 ratio combined diagnosis with AFP exhibited the capability of increasing the detection efficacy and specificity of AFP for HCC and AFP-negative HCC. The incidence of LC and HCC in the respective logistic regression model showed a negative correlation with the serum ApoB/ApoA1 ratio in CHB patients (P < 0.05). After all confounding factors covered in this study were regulated, the result of the restricted cubic spline analysis suggested that in a certain range, serum ApoB/ApoA1 ratio showed an inverse correlation with the prevalence of LC or HCC in CHB patients. Serum ApoB/ApoA1 ratio in CHB patients may be conducive to identifying high-risk patients for HCC or LC, such that LC and HCC can be early diagnosed and treated.

show abstract

Section: Blood Sampling and Analysismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Serum ApoB/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma

Cai,

Peng,

Xiao

et al. 2024

Sci Rep

View full text Add to dashboard Cite

show abstract

Co-infection of hepatitis E virus, Clonorchis sinensis, and Escherichia coli: A case report

Zhang

Wang

Zhang

et al. 2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Hepatitis E virus (HEV) is a common cause of acute hepatitis that threatens human health worldwide. With the popularization of detection technology, the reports of hepatitis E have gradually increased. Here, we present a rare case of co-infection with hepatitis E viruses, Clonorchis sinensis and Escherichia coli. A 52-year-old man was hospitalized because of fatigue, jaundice, and nausea for more than 2 weeks. Laboratory tests showed elevated bilirubin, aminotransferase (ALT), and aspartate aminotransferase (AST); HEV-IgM was positive, and HEV-RNA could be detected. Moreover, parasites were found in the biliary drainage and the biliary culture, which suggested Escherichia coli. The patient was effectively treated with praziquantel, imipenem, and hepatoprotective drugs and his clinical symptoms were relieved after 2 months; total bilirubin decreased to 85.1 μmol/L, ALT decreased to 92.4 U/L, and AST decreased to 102 U/L.

show abstract

The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview

Marascio

Quirino

et al. 2022

JCM

View full text Add to dashboard Cite

Hepatitis C virus (HCV) still represents one of the most important worldwide health care problems. Since 2011, direct-acting antiviral (DAA) drugs have increased the number of people who have achieved a sustained virological response (SVR). Even if the program to eradicate HCV by 2030 is still ongoing, the SARS-CoV-2 pandemic has created a delay due to the reallocation of public health resources. HCV is characterized by high genetic variability and is responsible for hepatic and extra-hepatic diseases. Depending on the HCV genotype/subtype and comorbidities of patients, tailored treatment is necessary. Recently, it has been shown that liver damage impacts gut microbiota, altering the microbial community (dysbiosis) during persistent viral replication. An increasing number of studies are trying to clarify the role of the gut–liver axis during HCV chronic infection. DAA therapy, by restoring the gut microbiota equilibrium, seems to improve liver disease progression in both naïve and treated HCV-positive patients. In this review, we aim to discuss a snapshot of selected peer-reviewed papers concerning the interplay between HCV and the gut–liver axis.

show abstract

Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice

Cited by 4 publications

References 92 publications

Serum ApoB/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma

Serum ApoB/ApoA1 ratio in patients with CHB and the occurrence of HBV related cirrhosis and HBV related hepatocellular carcinoma

Co-infection of hepatitis E virus, Clonorchis sinensis, and Escherichia coli: A case report

The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview

Contact Info

Product

Resources

About